Building A Better Biomarker: PD-L1 Expression Under Spotlight At ASCO
With new data showing correlation to response, use of PD-L1 expression as a biomarker for PD-1/L1 inhibitors was a frequent topic at ASCO. Its limitations point to need for better markers to guide immunotherapy use.
You may also be interested in...
Survey of recent literature shows breadth and quality of early research activity aimed at developing biomarkers to predict response to PD-1 and CTLA-4 checkpoint inhibitors.
The US FDA granted an accelerated approval to Sarepta’s Elevidys, the first gene therapy to be approved for some children with Duchenne muscular dystrophy.
The deadline is approaching for submissions to the 2023 Citeline Awards; gain recognition for your clinical research team, real world evidence project, diversity and inclusion efforts, and more.